Diabetic Nephropathy and Hachimi-jio-gan

[Guest guest]

Thought this was interesting.

 

Enjoy,

 

Chris

 

 

 

 

 

 

Journal Home

Editorial Board

Guidelines

Issues

 

 

 

 

 

Advertising

Subscriptions

Free Alert

Online Sample

 

 

 

 

 

 

 

 

 

Vol. 97, No. 2, 2004

 

Free Abstract Article (Fulltext) Article (PDF 283 KB)

 

 

 

Original Paper

A Study on the Effects to Diabetic Nephropathy of Hachimi-jio-gan in Rats

Takako Yokozawaa, Noriko Yamabea, Eun Ju Choa, Takako Nakagawaa, Shigeru

Oowadab

 

aInstitute of Natural Medicine, Toyama Medical and Pharmaceutical University,

Toyama and

bFirst Department of Internal Medicine, St. Marianna University School of M

edicine, Kanagawa, Japan

 

Address of Corresponding Author

Nephron Experimental Nephrology 2004;97:e38-e48 (DOI: 10.1159/000078405)

 

 

 

Key Words

Hachimi-jio-gan

Diabetic nephropathy

Advanced glycation end-products

Sorbitol

Lipid peroxidation

Glomerular sclerosis

Tubulointerstitial lesion

 

 

 

Abstract

To investigate the effects of Hachimi-jio-gan on diabetic nephropathy, we

employed an animal model, rats subjected to sub-total nephrectomy followed by

streptozotocin injection, and administered Hachimi-jio-gan orally at a dose of

50, 100 or 200 mg/kg body weight/day for 15 weeks. The administration of

Hachimi-jio-gan reduced dose-dependently the elevated blood glucose and urinary

protein excretion levels in rats with diabetic nephropathy over the experimental

period, whereas it increased creatinine clearance significantly, suggesting that

Hachimi-jio-gan would prevent or delay the progression of diabetic

nephropathy. In addition, the serum glycosylated protein and urea nitrogen

levels were

markedly elevated in rats with diabetic nephropathy compared with normal rats,

and were significantly reduced by the administration of Hachimi-jio-gan,

whereas Hachimi-jio-gan reversed the decrease in the serum albumin level. The

serum

triglyceride and total cholesterol concentrations were reduced by

Hachimi-jio-gan, implying that Hachimi-jio-gan would improve the metabolic

disorder of

lipids caused by diabetic nephropathy. Moreover, Hachimi-jio-gan inhibited lipid

peroxidation in the serum and kidney, which suggests that Hachimi-jio-gan

would ameliorate oxidative stress associated with diabetic nephropathy.

Furthermore, the disorders of the glucose-dependent metabolic pathway due to

this

pathological condition were also normalized by the administration of

Hachimi-jio-gan through decreases in advanced glycation end-product formation

and sorbitol

levels in the kidney. Hachimi-jio-gan protected against the development of

renal lesions, glomerular sclerosis, tubulointerstitial lesions, mesangial

matrix

expansion and arteriolar sclerosis, estimated by histopathological evaluation

and scoring. This study suggests that Hachimi-jio-gan may be a novel

therapeutic approach to improving diabetic nephropathy.

2004 S. Karger AG, Basel

 

 

 

Author Contacts

Dr. Takako Yokozawa

Institute of Natural Medicine

Toyama Medical and Pharmaceutical University

2630 Sugitani, Toyama 930-0194 (Japan)

Tel. +81 76 4347631, Fax +81 76 4344656, E-Mail yokozawa

 

 

 

Article Information

Received: December 2, 2003

Accepted: January 8, 2004

Number of Print Pages : 11

Number of Figures : 3, Number of Tables : 4, Number of References : 49